

Product datasheet

Recombinant Human Prosurfactant Protein C ab114293

1 Image

Description

Product name	Recombinant Human Prosurfactant Protein C
Expression system	Wheat germ
Accession	<u>P11686</u>
Protein length	Full length protein
Animal free	No
Nature	Recombinant
Species	Human
Sequence	MDVGSKEVLMESPPDYSAAPRGRFGIPRCPVHLKRLIV VVVVLIVVI VGALLMGLHMSQKHEMVLMSIGAPEAQQRLALSEHLV TTATFSIGSTG LVVYDYQQLLIAYKPAPGTCCYIMKIAPESIPSLEALNRKVH NFQMECSL QAKPAVPTSKLGQAEGRDAGSAPSGGDP AFLGMAVN TL CGEVPLYYI
Predicted molecular weight	47 kDa including tags
Amino acids	1 to 197
Description	Recombinant Human Prosurfactant Protein C

Specifications

Our **Abpromise guarantee** covers the use of **ab114293** in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Applications	Western blot ELISA SDS-PAGE
Form	Liquid

Preparation and Storage

Stability and Storage Shipped on dry ice. Upon delivery aliquot and store at -80°C. Avoid freeze / thaw cycles.

pH: 8.00

Constituents: 0.3% Glutathione, 0.79% Tris HCl

General Info

Function

Pulmonary surfactant associated proteins promote alveolar stability by lowering the surface tension at the air-liquid interface in the peripheral air spaces.

Involvement in disease

Defects in SFTPC are the cause of pulmonary surfactant metabolism dysfunction type 2 (SMDP2) [MIM:610913]; also called pulmonary alveolar proteinosis due to surfactant protein C deficiency. A rare disease associated with progressive respiratory insufficiency and lung disease with a variable clinical course, due to impaired surfactant homeostasis. It is characterized by alveolar filling with floccular material that stains positive using the periodic acid-Schiff method and is derived from surfactant phospholipids and protein components. Excessive lipoproteins accumulation in the alveoli results in severe respiratory distress.

Genetic variations in SFTPC are a cause of susceptibility to respiratory distress syndrome in premature infants (RDS) [MIM:267450]; also known as RDS in prematurity. RDS is a lung disease affecting usually premature newborn infants. It is characterized by deficient gas exchange, diffuse atelectasis, high-permeability lung edema and fibrin-rich alveolar deposits called 'hyaline membranes'.


Sequence similarities

Contains 1 BRICHOS domain.

Cellular localization

Secreted > extracellular space > surface film.

Images



ab114293 analysed on a 12.5% SDS-PAGE gel stained with Coomassie Blue.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish

- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit <https://www.abcam.com/abpromise> or contact our technical team.

Terms and conditions

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors